Laboratory Biomarker Analysis Clinical Trials
46 recruitingOther
Phase 222Phase 18Not Applicable3Phase 32Early Phase 11
Showing 1–20 of 46 trials
Recruiting
Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
Hematopoietic and Lymphoid Cell NeoplasmMalignant NeoplasmHealthy Subject+2 more
University of Southern California625 enrolled1 locationNCT03207854
Recruiting
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
Breast CarcinomaNeuropathy
National Cancer Institute (NCI)575 enrolled1 locationNCT02610439
Recruiting
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
Breast Carcinoma
National Cancer Institute (NCI)162 enrolled1 locationNCT02610426
Recruiting
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
Breast Carcinoma
National Cancer Institute (NCI)354 enrolled1 locationNCT02610413
Recruiting
Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
High Risk Myelodysplastic SyndromeMyelodysplastic Syndrome With Excess Blastsde Novo Myelodysplastic Syndrome+7 more
M.D. Anderson Cancer Center270 enrolled1 locationNCT00801489
Recruiting
Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7
ECOG-ACRIN Cancer Research Group82 enrolled140 locationsNCT03493425
Recruiting
Phase 2
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Head and Neck Squamous Cell CarcinomaStage III Hypopharyngeal Carcinoma AJCC v8Stage III Laryngeal Cancer AJCC v8+13 more
ECOG-ACRIN Cancer Research Group189 enrolled640 locationsNCT02734537
Recruiting
Phase 2
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Chronic Myelomonocytic LeukemiaRecurrent LymphomaRecurrent Diffuse Large B-Cell Lymphoma+5 more
Mayo Clinic80 enrolled4 locationsNCT03418038
Recruiting
Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia
City of Hope Medical Center74 enrolled1 locationNCT03422731
Recruiting
Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Malignant Solid NeoplasmClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+41 more
M.D. Anderson Cancer Center800 enrolled1 locationNCT03819296
Recruiting
Not Applicable
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
Recurrent Adult Soft Tissue Sarcoma
Jonsson Comprehensive Cancer Center51 enrolled1 locationNCT02701153
Recruiting
Phase 2
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center50 enrolled1 locationNCT01746836
Recruiting
Not Applicable
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
Estrogen Receptor Negative
M.D. Anderson Cancer Center120 enrolled8 locationsNCT02945579
Recruiting
Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
CholangiocarcinomaBenign Liver TumorAdult Hepatocellular Carcinoma+2 more
M.D. Anderson Cancer Center110 enrolled1 locationNCT02379377
Recruiting
Phase 1
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
Recurrent Adult Acute Myeloid LeukemiaPreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Lymphoblastic Leukemia+1 more
University of Chicago30 enrolled1 locationNCT02333162
Recruiting
Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix
Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type
M.D. Anderson Cancer Center70 enrolled1 locationNCT05046080
Recruiting
Not Applicable
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
Lung AdenocarcinomaCigarette SmokerCurrent Smoker+2 more
Ohio State University Comprehensive Cancer Center3,584 enrolled1 locationNCT03199651
Recruiting
Phase 2
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Mayo Clinic120 enrolled3 locationsNCT03516617
Recruiting
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
Malignant Solid NeoplasmRecurrent Prostate CarcinomaStage IV Bladder Cancer AJCC v7+8 more
University of Washington1,500 enrolled1 locationNCT01050504
Recruiting
Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Grade 2 MeningiomaIntracranial Meningioma
NRG Oncology163 enrolled214 locationsNCT03180268